Efficacy of canakinumab in mild or severe COVID-19 pneumonia.

Falasca KatiaDi Penta MyriamUcciferri Claudio Antonio Auricchio Marta Di Nicola Michele MarchioniCelletti EleonoraSabatini EmanuelaFrancesco Cipollone Jacopo Vecchiet

Published in: Immunity, inflammation and disease (2021)

In hospitalized adult patients with mild or severe non ICU COVID-19, canakinumab could be a valid therapeutic option. Canakinumab therapy causes rapid and long-lasting improvement in oxygenation levels in the absence of any severe adverse events.

Keyphrases

coronavirus disease
sars cov
early onset
intensive care unit
stem cells
bone marrow
cell therapy